Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the fourteen analysts that are currently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $30.56.
A number of equities research analysts have recently commented on KROS shares. HC Wainwright cut their target price on Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Bank of America cut Keros Therapeutics from a "buy" rating to a "neutral" rating and cut their target price for the stock from $32.00 to $18.00 in a research note on Tuesday, June 10th. Truist Financial cut their target price on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a research note on Wednesday, April 9th. Wedbush reissued a "neutral" rating and issued a $15.00 target price on shares of Keros Therapeutics in a research note on Friday, May 30th. Finally, Scotiabank dropped their price objective on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a research report on Monday, May 12th.
View Our Latest Stock Report on KROS
Keros Therapeutics Price Performance
KROS stock traded up $0.41 during midday trading on Friday, hitting $14.32. The stock had a trading volume of 599,913 shares, compared to its average volume of 866,049. The firm has a market cap of $581.68 million, a price-to-earnings ratio of -79.56 and a beta of 1.26. The business has a 50-day moving average of $13.97 and a two-hundred day moving average of $12.82. Keros Therapeutics has a 52-week low of $9.12 and a 52-week high of $72.37.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $3.63. The company had revenue of $211.25 million for the quarter, compared to analysts' expectations of $84.62 million. Keros Therapeutics had a return on equity of 0.75% and a net margin of 1.96%. During the same period in the prior year, the firm earned ($1.21) earnings per share. Research analysts predict that Keros Therapeutics will post -4.74 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. FNY Investment Advisers LLC purchased a new position in Keros Therapeutics in the first quarter worth about $25,000. CWM LLC boosted its position in Keros Therapeutics by 10,157.7% in the first quarter. CWM LLC now owns 2,667 shares of the company's stock worth $27,000 after purchasing an additional 2,641 shares during the last quarter. AlphaQuest LLC boosted its position in Keros Therapeutics by 469.0% in the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock worth $57,000 after purchasing an additional 2,964 shares during the last quarter. Virtus ETF Advisers LLC boosted its position in Keros Therapeutics by 107.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock worth $61,000 after purchasing an additional 1,998 shares during the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in Keros Therapeutics in the fourth quarter worth about $90,000. 71.56% of the stock is owned by hedge funds and other institutional investors.
About Keros Therapeutics
(
Get Free ReportKeros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
Recommended Stories

Before you consider Keros Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.
While Keros Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.